BioCentury | Mar 6, 2021
Finance

CRISPR stocks track ETFs lower: Data Byte

...basket of gene editing stocks.Gene editing companies CRISPR Therapeutics AG (NASDAQ:CRSP), Editas Medicine Inc. (NASDAQ:EDIT), Intellia Therapeutics Inc....
...or visual content" frameborder="0" scrolling="no" style="width:100%;height:600px;" sandbox="allow-same-origin allow-forms allow-scripts allow-downloads allow-popups allow-popups-to-escape-sandbox allow-top-navigation-by-user-activation"> Stephen Hansen CRISPR Therapeutics AG Intellia Therapeutics Inc. Editas...
BioCentury | Feb 27, 2021
Product Development

The growing pool of gene editing delivery companies

...developing in vivo delivery technologies, while others have been signing deals to build their delivery toolboxes.Intellia Therapeutics Inc....
...content" frameborder="0" scrolling="no" style="width:100%;height:550px;" sandbox="allow-same-origin allow-forms allow-scripts allow-downloads allow-popups allow-popups-to-escape-sandbox allow-top-navigation-by-user-activation"> Lauren Martz Beam Therapeutics Inc. CRISPR Therapeutics AG Intellia Therapeutics Inc. Editas...
BioCentury | Feb 17, 2021
Finance

CRISPR stocks begin to converge in the clinic: Data Byte

...current valuation of the Phase I/II company is over $11 billion. Editas Medicine Inc. (NASDAQ:EDIT) and Intellia Therapeutics Inc....
...content" frameborder="0" scrolling="no" style="width:100%;height:600px;" sandbox="allow-same-origin allow-forms allow-scripts allow-downloads allow-popups allow-popups-to-escape-sandbox allow-top-navigation-by-user-activation"> Lauren Martz Editas Medicine Inc. CRISPR Therapeutics AG Intellia Therapeutics Inc....
BioCentury | Feb 17, 2021
Deals

Feb. 17 Quick Takes: Vir, GSK expand partnership; plus Nektar; ImmuneID, Imcyse, Provention-Huadong and Novartis-Gates

...disease (SCD), which don’t require the complex infrastructure needed for ex vivo gene therapies. The pharma and Intellia Therapeutics Inc....
BioCentury | Feb 10, 2021
Deals

CRISPR play Caribou broadens therapeutics reach with AbbVie deal to develop allogeneic CAR Ts

...rights to the foundational CRISPR-Cas9 IP to Intellia Therapeutics Inc....
BioCentury | Feb 9, 2021
Product Development

KalVista gains on Phase II data for oral HAE treatment

...Plasma kallikrein Danielle Golovin KVD900 ATN-249 NTLA-2002 Kalbitor, ecallantide (CB-500,929, DX-88, EPI-KAL2, FV2302) Takhzyro (lanadelumab, lanadelumab-flyo, SHP643, dx-2930) KVD824 KalVista Pharmaceuticals Inc. Attune Pharmaceuticals Inc. Intellia Therapeutics Inc. Takeda...
BioCentury | Jan 15, 2021
Finance

A maturing mid-cap sector could keep funds flowing into biotech

...editing pioneers Editas Medicine Inc. (NASDAQ:EDIT) and Intellia Therapeutics Inc....
BioCentury | Dec 18, 2020
Product Development

2021 Predictions: a BioCentury survey

...elevated safety concerns around off-target edits. In November, Intellia Therapeutics Inc....
BioCentury | Dec 1, 2020
Emerging Company Profile

Spotlight: solving CRISPR’s delivery challenges with RNPs

...editing. The first systemically delivered therapy, NTLA-2001 from Intellia Therapeutics Inc....
...undisclosedCEO: Mary Haak-FrendschoPatents: None issued Lauren Martz Spotlight Therapeutics Inc. Intellia Therapeutics Inc. Editas...
BioCentury | Nov 11, 2020
Product Development

In vivo gene editing advances with Intellia’s trial start, grant

...CRISPR therapies for sickle cell disease. On Monday, Intellia Therapeutics Inc....
...of Intellia’s grant is undisclosed.TARGETSTTR – Transthyretin Lauren Martz NTLA-2001 Intellia Therapeutics Inc. Regeneron...
Items per page:
1 - 10 of 166
BioCentury | Mar 6, 2021
Finance

CRISPR stocks track ETFs lower: Data Byte

...basket of gene editing stocks.Gene editing companies CRISPR Therapeutics AG (NASDAQ:CRSP), Editas Medicine Inc. (NASDAQ:EDIT), Intellia Therapeutics Inc....
...or visual content" frameborder="0" scrolling="no" style="width:100%;height:600px;" sandbox="allow-same-origin allow-forms allow-scripts allow-downloads allow-popups allow-popups-to-escape-sandbox allow-top-navigation-by-user-activation"> Stephen Hansen CRISPR Therapeutics AG Intellia Therapeutics Inc. Editas...
BioCentury | Feb 27, 2021
Product Development

The growing pool of gene editing delivery companies

...developing in vivo delivery technologies, while others have been signing deals to build their delivery toolboxes.Intellia Therapeutics Inc....
...content" frameborder="0" scrolling="no" style="width:100%;height:550px;" sandbox="allow-same-origin allow-forms allow-scripts allow-downloads allow-popups allow-popups-to-escape-sandbox allow-top-navigation-by-user-activation"> Lauren Martz Beam Therapeutics Inc. CRISPR Therapeutics AG Intellia Therapeutics Inc. Editas...
BioCentury | Feb 17, 2021
Finance

CRISPR stocks begin to converge in the clinic: Data Byte

...current valuation of the Phase I/II company is over $11 billion. Editas Medicine Inc. (NASDAQ:EDIT) and Intellia Therapeutics Inc....
...content" frameborder="0" scrolling="no" style="width:100%;height:600px;" sandbox="allow-same-origin allow-forms allow-scripts allow-downloads allow-popups allow-popups-to-escape-sandbox allow-top-navigation-by-user-activation"> Lauren Martz Editas Medicine Inc. CRISPR Therapeutics AG Intellia Therapeutics Inc....
BioCentury | Feb 17, 2021
Deals

Feb. 17 Quick Takes: Vir, GSK expand partnership; plus Nektar; ImmuneID, Imcyse, Provention-Huadong and Novartis-Gates

...disease (SCD), which don’t require the complex infrastructure needed for ex vivo gene therapies. The pharma and Intellia Therapeutics Inc....
BioCentury | Feb 10, 2021
Deals

CRISPR play Caribou broadens therapeutics reach with AbbVie deal to develop allogeneic CAR Ts

...rights to the foundational CRISPR-Cas9 IP to Intellia Therapeutics Inc....
BioCentury | Feb 9, 2021
Product Development

KalVista gains on Phase II data for oral HAE treatment

...Plasma kallikrein Danielle Golovin KVD900 ATN-249 NTLA-2002 Kalbitor, ecallantide (CB-500,929, DX-88, EPI-KAL2, FV2302) Takhzyro (lanadelumab, lanadelumab-flyo, SHP643, dx-2930) KVD824 KalVista Pharmaceuticals Inc. Attune Pharmaceuticals Inc. Intellia Therapeutics Inc. Takeda...
BioCentury | Jan 15, 2021
Finance

A maturing mid-cap sector could keep funds flowing into biotech

...editing pioneers Editas Medicine Inc. (NASDAQ:EDIT) and Intellia Therapeutics Inc....
BioCentury | Dec 18, 2020
Product Development

2021 Predictions: a BioCentury survey

...elevated safety concerns around off-target edits. In November, Intellia Therapeutics Inc....
BioCentury | Dec 1, 2020
Emerging Company Profile

Spotlight: solving CRISPR’s delivery challenges with RNPs

...editing. The first systemically delivered therapy, NTLA-2001 from Intellia Therapeutics Inc....
...undisclosedCEO: Mary Haak-FrendschoPatents: None issued Lauren Martz Spotlight Therapeutics Inc. Intellia Therapeutics Inc. Editas...
BioCentury | Nov 11, 2020
Product Development

In vivo gene editing advances with Intellia’s trial start, grant

...CRISPR therapies for sickle cell disease. On Monday, Intellia Therapeutics Inc....
...of Intellia’s grant is undisclosed.TARGETSTTR – Transthyretin Lauren Martz NTLA-2001 Intellia Therapeutics Inc. Regeneron...
Items per page:
1 - 10 of 166